If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Most 1. Bundesliga goals scored: 72 – Vincenzo Grifo 8 May 2026 Highest transfer fee paid: €10 million for Baptiste Santamaria Highest transfer fee received: €60million for Johan Manzambi Youngest goalscorer: Matthias Ginter – 18 years, 2 days Player who has scored the most against club: Claudio Pizarro – 14 goals in 17 matches Biggest home win: 6–0 – against Rot-Weiß Erfurt on 24 August 1991 Biggest 1. Bundesliga home win: 5–0 – against Hansa Rostock on 17 September 1999, against VfL Bochum on 9 December 2000 and against SV Werder Bremen on 21 February 2025 Biggest away win: 6–0 – against Borussia Mönchengladbach on 5 December 2021 Biggest 1. Bundesliga away win: 6–0 – against Borussia Mönchengladbach on 5 December 2021 Biggest home loss: 0–6 – against Bayern Munich on 16 December 2003 and against Werder Bremen on 4 December 2004 and 21 November 2009 Biggest 1. Bundesliga home loss: 0–6 – against Bayern Munich on 16 December 2003 and against Werder Bremen on 4 December 2004 and 21 November 2009 Biggest away loss: 0–7 – against Bayern Munich on 10 September 2011 Biggest 1. Bundesliga away loss: 0–7 – against Bayern Munich on 10 September 2011
The oldest known fabric dyed indigo, dated to 6,000 years ago, was discovered in Huaca Prieta, Peru. Many Asian countries, such as India, China, Japan, and Southeast Asian nations have used indigo as a dye (particularly for silk) for centuries. The dye was also known to ancient civilizations in Mesopotamia, Egypt, Britain, Mesoamerica, Peru, Iran, and West Africa. Indigo was also cultivated in India, which was also the earliest major center for its production and processing. The Indigofera tinctoria species was domesticated in India. Indigo, used as a dye, made its way to the Greeks and the Romans, where it was valued as a luxury product. In Mesopotamia, a neo-Babylonian cuneiform tablet of the seventh century BC gives a recipe for the dyeing of wool, where lapis-colored wool (uqnatu) is produced by repeated immersion and airing of the cloth. Indigo was most probably imported from India. The Romans used indigo as a pigment for painting and for medicinal and cosmetic purposes. It was a luxury item imported to the Mediterranean from India by Arab merchants.
=== Ancient history === There have been reports of stupor-like and catatonia-like states in people throughout the history of psychiatry. In ancient Greece, the first physician to document stupor-like or catatonia-like states was Hippocrates, in his Aphorisms. He never defined the syndrome, but seemingly observed these states in people he was treating for melancholia. In ancient China, the first descriptions of people that appear in the Huangdi Neijing (The Yellow Emperor's Inner Canon), the book which forms the basis of Traditional Chinese Medicine. It is thought to have been compiled by many people over the course of centuries during the Warring States Period (475-221 BCE) and the early Han Dynasty (206 BCE-220 CE).
==== 8 April ==== In Iran, the Lavan Oil Refinery, located on Lavan Island was struck at around 10 a.m.; a fire ignited. The Iranian authorities denounced the event and stated that it was an act of "cowardice" by the "enemies". Israel denied being involved in the attack. The debris of a drone shot down by Iranian forces killed a 7-year-old child and injured another six members of the child's family in the town of Shushtar in Khuzestan province.
Sources: en.wikipedia.org
These ultrafine particles are small enough to bypass respiratory defenses and be inhaled deep into the lungs, where they can enter the bloodstream and are associated with severe systemic inflammation, cardiovascular disease, and premature death. Many e-cigarette companies market their products as a smoking cessation aid without evidence of effectiveness. E-cigarette marketing has been found to make unsubstantiated health statements (e.g., that they help one quit smoking) including statements about improving psychiatric symptoms, which may be particularly appealing to smokers with mental illness. E-cigarette marketing advocate weight control and emphasize use of nicotine with many flavors. These marketing angles could particularly entice overweight people, young people, and vulnerable groups. Some e-cigarette companies state that their products are green without supporting evidence which may be purely to increase their sales.
This delivery method gained worldwide recognition during COVID-19 pandemic with the approval of mRNA vaccines from Pfizer-BioTech and Moderna. The rapid rollout of these vaccines proved that LNPs are not only effective but also scalable for mass production and global use. Looking beyond vaccines, mRNA therapies are now being explored for a range of therapeutic applications including cancer immunotherapy, genetic disorders, and other infectious diseases. Researchers are also testing alternative delivery systems, like exosomes and new types of nanoparticles, to make mRNA therapies safer and more efficient. However, challenges remain, as mRNA is highly sensitive to environmental conditions. To address this, ongoing research is expanding into new administration routes including inhalable or oral mNRA formulations. This could reduce production costs and make these therapies more accessible to the world.
The end goal of wound care is to re-establish the integrity of the skin, a structure which serves as a barrier to the external environment. The preferred method of closure is to reattach/reapproximate the wound edges together, a process known as primary closure/healing by primary intention. Wounds that have not been closed within several hours of the initial injury or wounds that are concerning for infection will often be left open and treated with dressings for several days before being closed 3–5 days later, a process known as delayed primary closure. The exact duration of time from initial injury in which delayed primary closure is preferred over primary closure is not clearly defined. Wounds that cannot be closed primarily due to substantial tissue loss can be healed by secondary intention, a process in which the wound is allowed to fill-in over time through natural physiologic processes. When healing by secondary intention, granulation tissue grows in from the wound edges slowly over time to restore integrity of the skin. Healing by secondary intention can take up to months, requires daily wound care, and leaves an unfavorable scar, thus primary closure is always preferred when possible. As an alternative, wounds that cannot be closed primarily can be addressed with skin grafting or flap reconstruction, typically done by a plastic surgeon. There are several methods that can be implemented to achieve primary closure of a wound, including suture, staples, skin adhesive, and surgical strips. Suture is the most frequently used for closure.
Sources: en.wikipedia.org
Bilberries are found in acidic, nutrient-poor soils throughout the temperate and subarctic regions of the world. Because they are difficult to grow and the fruit is small, bilberries are seldom cultivated. Fruits are mostly collected from wild plants growing on publicly accessible lands throughout northern and central Europe where they are plentiful; for example, bilberries occur on about 17% of the land area of Sweden, where the berry is called blåbär (lit. "blueberry", which is a source of confusion with the North American blueberry). Bilberries can be picked by a berry-picking rake like lingonberries, but are more susceptible to damage. In Iceland, bilberries (known as aðalbláber, or "prime blueberry") grow predominantly in Westfjords and the surrounding area. In most of the country, the subtype bog blueberry occupies the same habitat. Both species are commonly found growing with dwarf birch and crowberries. Wild growth is vast compared to the population of Iceland and wild harvesting is legal, and a common activity in August when the berry season peaks. In Ireland, bilberries (known as fraochán) were traditionally gathered on the last Sunday in July, known as Bilberry Sunday, for the Celtic harvest festival of Lughnasadh, which marked the end of the hungry month of July.
== Political parties == Parti Communiste Réunionnais or Communist Party of Réunion Partido Comunista Revolucionário or Revolutionary Communist Party Partido Cívico Renovador or Civic Renovation Party, Dominican Republic Partidul Comunist Român or Romanian Communist Party
Robert Blake, Assistant Secretary of State for South and Central Asian Affairs, dismissed any concerns over a rift with India regarding American Af-Pak policy. Calling India and the United States "natural allies", Blake said that the United States cannot afford to meet the strategic priorities in Pakistan and Afghanistan at "the expense of India". India criticized the Obama administration's decision to limit H-1B (temporary) visas, and India's then External Affairs Minister Pranab Mukherjee (later, the president of India until 2017) said that India would oppose US "protectionism" at various international forums. India's Commerce Minister Kamal Nath said that India may move against Obama's outsourcing policies at the World Trade Organization. In May 2009, Obama reiterated his anti-outsourcing views and criticized the current US tax policy "that says you should pay lower taxes if you create a job in Bangalore, India, than if you create one in Buffalo, New York." However, during the US India Business Council meeting in June 2009, U.S. Secretary of State Hillary Clinton advocated for stronger economic ties between India and the United States. She also rebuked protectionist policies, saying that the U.S will not use the 2008 financial crisis as an excuse to implement protectionism. In June 2010, the United States and India formally re-engaged the US-India Strategic Dialogue initiated under President Bush when a large delegation of high-ranking Indian officials, led by External Affairs Minister S. M. Krishna, visited Washington, D.C.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.